301-315 of 894
Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
Project Oncology®Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®Diagnosing LCNEC of the Lung: Challenges and Strategies
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®Personalizing Care for Large Cell Neuroendocrine Carcinoma
Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Project Oncology®Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
- advertisement
Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Project Oncology®Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Project Oncology®Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
- advertisement
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease









































